Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-02-01

Summary

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.

• Phase: PHASE2

Details

• Lead Sponsor: Angitia Incorporated Limited